Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oligodeoxynucleotide intervention for prevention and treatment of sepsis

Inactive Publication Date: 2005-01-27
CYTOGENIX INC
View PDF22 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0034] The present invention comprises a method for delivering the ODN-expressing plasmid constructions into host cells in vivo so that, when the ODNs are produced

Problems solved by technology

The incidence of this condition is rising due to the aging of the population and increasing numbers of immuno-compromised and critically ill patients.
However, a deficient immunologic defense may allow infection to become established.
Further, an excessive or poorly regulated response may harm the host through maladaptive release of indigenously generated inflammatory compounds.
Additionally, diabetic individuals or others who suffer from lymphedema, especially in the feet and legs, are at risk of infection from exogenous opportunistic pathogens normally present on the skin due to the growth potential afforded by the edematous medium or the lack of circulation.
Such infections may result in severe cellulitis or related sequelae that can lead to sepsis.
This uncontrolled cascade of inflammation and coagulation fuels the progression of sepsis, resulting in hypoxia, widespread ischemia, organ dysfunction, and ultimately death for a large number of patients.
However, despite some encouraging results from early studies, none of the anti-endotoxin strategies have been shown to be of benefit in large clinical trials.
However, anti-TNF or anti-IL-1 antibodies have yet to be demonstrated any beneficial effect in sepsis or septic shock (Abraham et al., 1998, Lancet, 351, 929-933).
While theoretical and experimental animal evidence exists supporting the use of large doses of corticosteroids in severe sepsis and septic shock, all randomized human studies found that corticosteroids do not prevent the development of septic shock, reverse the shock state, or improve mortality.
However, treatment with this drug results in relatively modest improvements in patient mortality, and at the price of a slight increase in bleeding events (Id.).
Unfortunately, numerous classes of antibiotics have become less effective as a result of the rapid emergence of antibiotic resistance by many common bacterial pathogens such as S. aureus, Streptococcus pneumoniae and Enterococcus faecalis (Nicolaou & Boddy, 2001, Scientific American, p.56-61).
Although these approaches make a significant contribution to fighting against bacterial infections, difficulty remains in meeting the increasing needs of the medical community.
However, antisense technology is not used extensively in prokaryotic systems.
On the other hand, sepsis represents an excessive innate immune response to microbial products, and many processes in the complex pathophysiology of sepsis are simultaneously over-activated.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligodeoxynucleotide intervention for prevention and treatment of sepsis
  • Oligodeoxynucleotide intervention for prevention and treatment of sepsis
  • Oligodeoxynucleotide intervention for prevention and treatment of sepsis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Development of the Mouse Sepsis Model

[0050]E. coli SM101, a temperature-sensitive UDP-N-acetylglucosamine acyltransferase mutant that lose all detectable acyltransferase activity, and its wild-type K12, were i.p. injected as described below to induce sepsis in mouse. SM101 has a defect in lipid A biosynthesis that causes the outer membrane to be permeable to high-molecular-weight substances. The lipid A content of SM101 is reduced 2-3-fold compared with the wild-type. To prepare the bacteria for mouse infection, SM101 were grown in LB medium at 37° C. Log-phase cultures of SM101 were grown to an optical density at 600 nm of 1.1 (equivalent to 5×108 CFU / ml), followed by centrifugation and resuspension in sterile phosphate-buffered saline (PBS) at 4° C. This log-phase preparation of bacteria was serially diluted in PBS, and 3×10e8 CFU of bacteria was i.p. injected to induce mouse sepsis. Serum was gathered and pro-inflammatory cytokines (IL-6, TNF, IL-1) and bacterial load tested, an...

example 2

Inhibition of Bacterial Growth by ODN

[0051] The inhibition of bacterial growth by ODN was evaluated by examining the effect of DNA dose on the ability of ODN to inhibit SM101 growth. In this study, an ODN having the sequence CTC ATA CTC T was added to the 1 / 50 diluted O / N SM101 cell cultures, at final concentration of 40 μM or 400 μM, with addition of equal volume water as a negative control, and incubated with shaking at 30° C. After 2, 4 or 6 h, the growth was measured by either the optical density at 600 nm (OD600) or viable cell count, which was done by diluting the cultures and plating them in triplicate on LB plates with streptomycin. As shown in FIG. 3, upon addition of ODN, cell growth was inhibited by 86-96%.

example 3

Inhibition of Bacterial Growth by ODN Expression Plasmid

[0052] In this study, the ODN expression plasmid As080103, having the sequence CYGXO80103 listed above, and plasmid pssxGb without ODN insert as negative control, were transformed into E. coli XL10-gold(kan). The resulting cell cultures were plated on LB media with chloramphenicol and incubated at 37° C. O / N. As shown in FIG. 4, no XL10-gold(kan) carrying ODN expression plasmid grew on the LB media.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Login to View More

Abstract

A method for producing ODNs in bacterial or fungal cells in vivo for treatment of sepsis so that, when the ODNs reach and knock down their target genes, and thereby kill bacterial or fungal cells or inhibit their growth, the bacterial or fungal accumulation in the bloodstream is held constant or diminished and the sepsis syndrome is reduced or eliminated. The invention also contemplates of certain ODNs for use in treatment of sepsis.

Description

CROSS REFERENCE TO RELATED APPLICATION [0001] The present application is a continuation-in-part of co-pending application Ser. No. 10 / 453,410, filed Jun. 3, 2003 and IDENTIFICATION OF NOVEL ANTIBACTERIAL AGENTS BY SCREENING THE SINGLE-STRANDED DNA EXPRESSION LIBRARY, and co-pending application Ser. No. 10 / 743,956, filed Dec. 23, 2003 and entitled OLIGODOXYNUCLEOTIDE (ODN) LIBRARIES, THEIR USE IN SCREENING FOR ANTIBACTERIAL AGENTS, AND CATALYTIC ODN SEQUENCE FOR USE AS AN ANTIBACTERIAL AGENT. Both of the applications listed in this paragraph are hereby incorporated into the specification of the present application in their entirety by this specific reference thereto.BACKGROUND OF THE INVENTION [0002] Severe sepsis and septic shock are life threatening complication of infections and the most common cause of death in intensive care units (Angus et al., 2001, Crit. Care Med., 29:1303-1310). Recent US and European surveys have estimated that severe sepsis accounts for 2-11% of all admiss...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00C07H21/04C09D7/00C12N1/21C12N5/071C12N5/10C12N15/10C12N15/113C12N15/63C12N15/74C12Q1/68
CPCC12N15/1034C12N15/111C12N15/113C12N15/74C12N2310/11C12N2310/111C12Q1/6837C12N2320/11C12N2330/31C07H21/04C12Q2565/531A61P31/04A61P31/10C12N15/63C12N2310/127
Inventor CHEN, YINTAN, XIN
Owner CYTOGENIX INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products